Trellis Bioscience, Inc.

Stefan Ryser

Lawrence M Kauvar

Angeles Estelles

Lauren Opremcak Bakaletz

Steven David Goodman

Reyna J Simon

Mikhail Gishizky

Binding agents able to disrupt bacterial biofilms of diverse origin are described, including monoclonal antibodies secreted by human B lymphocytes. Methods to prevent formation of or to dissolve biofilms with these binding agents are also described. Immunogens for eliciting antibodies to disrupt biofilms are also described.

Binding moieties for biofilm remediation

Monoclonal antibodies derived from the native human repertoire that bind the extracellular portion of Killer IgG Receptor (KIR) and pharmaceutical and veterinary compositions thereof are useful in treating cancer in human and other subjects.

Monoclonal antibodies targeting killer immunoglobulin-like receptor (KIR) family signaling

Novel monoclonal antibodies directed against immune checkpoint modulator (ICM) proteins TIM-3 and B7-H3 are useful in treating cancer and immune system disorders.

Native human antibodies for immune checkpoint modulation targets TIM-3 and B7-H3

Binding agents able to disrupt bacterial biofilms of diverse origin are described, including monoclonal antibodies suitable for administration to a selected species, and antibody mimics including aptamer nucleic acids. Methods to prevent formation of or to dissolve biofilms with these binding agents are also described. Immunogens for eliciting antibodies to disrupt biofilms are also described.

Growing community of inventors

Menlo Park, CA, United States of America

Stefan Ryser